BOSTON--(BUSINESS WIRE)--MetaStat, Inc. (OTCQB:MTST), a personalized medicine company developing therapeutic and diagnostic treatment solutions for cancer patients, announced today accomplished drug developer, Renato T. Skerlj, Ph.D., has joined the company as a member of its Scientific and Clinical Advisory Board.
“MetaStat’s proprietary driver-based pan-cancer biomarkers are exciting targets for cancer drug development. They represent the promise of personalized medicine and the potential for new targeted cancer therapies that address major treatment challenges facing oncologists and their patients,” said Dr. Skerlj.
“I am especially delighted to welcome Dr. Skerlj to MetaStat’s SAB to help with our internal anti-metastatic drug development program. Renato’s knowledge, experience and successful track record are invaluable assets to help us efficiently advance our small molecule program that is aimed at preventing aggressive cancer from spreading,” stated Douglas. A. Hamilton, MetaStat’s President and CEO.
Dr. Skerlj serves as Vice President of Drug Discovery and Preclinical Development at Lysosomal Therapeutics Inc. Dr. Skerlj is a co-founder and a Member of Scientific Advisory Board of X4 Pharmaceuticals Inc. and co-founder of Noliva Therapeutics. He has over 25 years of pharmaceutical experience in drug development resulting in two marketed drugs: Invanz® and Mozobil® and multiple drugs in clinical development. Previously, Dr. Skerlj served as the Head of Small Molecule Discovery at Genzyme, prior to its acquisition by Sanofi. He served as Vice President of Chemistry for AnorMED Inc., a publicly-traded company acquired by Genzyme for $580 million in 2006. Prior to AnorMED Inc., Dr. Skerlj served as a Senior Research Chemist at Merck & Co., Inc. and Senior Scientist at Johnson Matthey's biomedical research group. Dr. Skerlj earned his doctorate from the University of British Columbia and completed a fellowship at the University of Oxford in Dr. Stephen Davies’ laboratory.
About MetaStat, Inc.
MetaStat is a biotechnology company focused on discovering and developing personalized therapeutic and diagnostic treatment solutions for cancer patients. Our Mena isoform “driver-based” diagnostic biomarkers also serve as novel therapeutic targets for anti-metastatic drugs. MetaStat is developing therapeutic product candidates and paired companion diagnostics based on a novel approach that makes the Mena isoform protein a druggable target. Our core expertise includes an understanding of the mechanisms and pathways that drive tumor cell invasion and metastasis, as well as drug resistance to certain targeted therapies and cytotoxic chemotherapies. MetaStat is based in Boston, MA.
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the company's Form 10-K and its other filings filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the company undertakes no obligation to update such statements.